The FDA has approved use of the meningococcal vaccine Menactra in children as young as age 9 months.

The vaccine had already been approved for use in children 2 years and older. In announcing its action on Friday, the agency noted that the highest rates of meningococcal disease occur in children under 1 year of age. With the new approval, the vaccine can be given in two doses, 3 months apart.

In safety studies, the most common adverse events among children ages 9 and 12 months were injection-site tenderness and irritability.

Source: FDA